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Background. Most patients with dengue experience mild disease, dengue fever (DF), while few develop the life-threatening 
diseases dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). No laboratory tests predict DHF or DSS. We evaluated 
whether the serum chymase level can predict DHF or DSS in adult and pediatric patients and the influence of preexisting conditions 
(PECs) on chymase levels.
Methods. Serum chymase levels were measured in patients presenting with undifferentiated fever to hospitals in Colombo 
District, Sri Lanka. The value of serum the chymase concentration and clinical signs and symptoms as predictors of DHF and/or 
DSS was evaluated by multivariate analysis. We assessed the influence of age, PECs, and day after fever onset on the robustness of the 
chymase level as a biomarker for DHF and/or DSS.
Results. An elevated chymase level in acute phase blood samples was highly indicative of later diagnosis of DHF or DSS for pedi-
atric and adult patients with dengue. No recorded PECs prevented an increase in the chymase level during DHF. However, certain 
PECs (obesity and cardiac or lung-associated diseases) resulted in a concomitant increase in chymase levels among adult patients 
with DHF.
Conclusions. These results show that patients with acute dengue who present with high levels of serum chymase consistently are 
at greater risk of DHF. The chymase level is a robust prognostic biomarker of severe dengue for adult and pediatric patients.
Keywords.  dengue virus; dengue fever; DHF/DSS; prognosis; biomarker; chymase; mast cells; pediatric dengue.
 
Dengue is an arboviral infection spread by mosquitoes in 
the tropical and subtropical regions of the world [1]. It is 
caused by dengue virus (DENV), which has 4 distinct sero-
types. Between 50 million and 400 million DENV infections 
occur yearly [2]. In DENV-endemic countries, such as the site 
of this study, Sri Lanka [3], many patients experience multi-
ple DENV infections in a lifetime. An incubation period of 
approximately 4–7 days occurs before fever onset [4, 5]. Signs 
such as leukopenia, thrombocytopenia, and rash and symp-
toms such as headache, vomiting, and retro-orbital eye pain 
are common during acute disease and usually resolve within 
3–7 days for those who experience mild disease, diagnosed as 
dengue fever (DF) [6, 7]. Mild hemorrhagic manifestations 
such as petechiae and purpura are also common during this 
time [6, 7]. Resolution of the febrile response usually occurs 
around days 4–7, when most patients completely recover, 
but other individuals can suddenly experience complications 
[6]. Warning signs have been identified to aid in recogniz-
ing patients on course to develop dengue hemorrhagic fever 
(DHF) or dengue shock syndrome (DSS), also known as 
severe dengue [8]. Warning signs include mucosal bleeding, 
liver enlargement, abdominal pain, rapid hematocrit increase, 
persistent vomiting, and clinical fluid accumulation [8]. Many 
of these signs are subjective and present very late. DHF and 
DSS are extremely difficult to predict, and there is an urgent 
need to identify risk factors and biomarkers of severe dengue. 
Although some studies associated high serum viral titers with 
DHF and DSS [9, 10], others have reported conflicting infor-
mation [11–13]. Multiple factors could explain these discrep-
ancies, including faster clearance of viremia during secondary 
infection [14, 15]. There is an unmet need for diagnostic tests 
to identify severe DENV during the acute phase of disease, 
since clinical symptoms often fail to predict it with sufficient 
warning, and to understand whether those tests are robust in 
multiple patient populations.
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Differences in the severity of DENV disease between adult and 
pediatric cases have been identified [16, 17]. For example, in 
recent outbreaks in the Philippines, the symptomatic disease 
burden primarily involved children [18]. In Thailand, signs such 
as epistaxis, oliguria, and liver enlargement were more prevalent 
among children than among adults [17]. It is unclear whether 
there may be differences in the pathophysiological mechanisms 
in pediatric and adult patients with dengue or whether prior 
immunity in the adult population can account for the observed 
differences in severity. One study suggested that children have 
an inherently higher capillary fragility, possibly explaining why 
small children present more often with DSS than adults do 
[19]. In contrast, in some populations, including residents of 
Singapore, morbidity and mortality are more common in adult 
and elderly patients, potentially because of the increased inci-
dence of comorbidities [20, 21]. Preexisting conditions (PECs) 
such as diabetes [22] and obesity [23] have also been associ-
ated with severe disease in some studies. The observation in the 
CYD-TDV (Dengvaxia) trials that a greater percentage of chil-
dren aged 2–5 years than those >5 years required hospitaliza-
tion within 3 years of infection emphasizes the importance of 
evaluating DENV diagnostic tests in multiple age groups [24].
In humans, immune pathology is thought to underlie severe 
disease [7]. One immune cell type, the mast cell (MC), is criti-
cal to the host response to DENV [25–27]. MCs are granulated 
cells that regulate the host vasculature during inflammation and 
homeostasis [28]. DENV activation of MCs prompts them to 
degranulate, which involves the release of their presynthesized 
inflammatory mediators from intracellular stores [26]. Most 
granule-associated mediators are proteases, including chymase, 
which is highly specific to MCs [29]. Chymase is a serine pro-
tease and angiotensin-converting enzyme [30]. MC degranula-
tion occurs rapidly. During anaphylaxis, MC-derived mediators 
are the underlying cause of shock and death and can be detected 
in the serum as biomarkers [31]. Our prior studies showed that 
DENV activates MCs, resulting in chymase release, and that 
MC activation is augmented by DENV-specific antibodies, as 
are present during secondary infections [25–27, 32]. This led to 
the observation in a retrospective study of adult DENV-infected 
patients in Singapore that chymase levels were elevated in acute-
phase serum samples from patients with DHF [25].
Here, we questioned whether the MC-derived protease 
chymase is a robust predictor of DHF and/or DSS in multi-
ple patient populations and we assessed whether PECs atten-
uate the predictive capacity of chymase. Febrile patients were 
recruited at study sites in Colombo District, Sri Lanka [3, 33]. 
Patients’ signs and symptoms were recorded, and their disease 
severity was documented. Acute-phase serum samples were 
used to measure the chymase level to assess its potential to pre-
dict DHF and/or DSS. Our analysis reveals that the chymase 
level is a prognostic biomarker for DHF and DSS in pediatric 
and adult patients, including those with PECs.
METHODS
Recruitment of and Collection of Samples From Patients With Dengue
Samples were prospectively obtained by the Ministry of Health 
in Sri Lanka and provided by the Dengue Tools Project [3, 33]. 
The Dengue Tools Project recruited patients with undifferenti-
ated febrile illness with a duration of <7 days, the onset of which 
was self-reported and may have been subjective. The number 
recruited was capped at 60 patients per week, with 10 from each 
study site. All patients provided blood samples with informed 
consent, which were anonymized. Samples from 347 patients 
were used, from 6 clinical sites in the Colombo district of Sri 
Lanka (3 government hospitals and 3 general practitioner’s 
clinics). Ethical approval was obtained from the Ethics Review 
Committee, Faculty of Medicine, University of Colombo, Sri 
Lanka, and the National University of Singapore Institutional 
Review Board. Parental consent was obtained for participants 
aged <18 years. Serum samples collected from patients at the 
time of recruitment were selected for chymase testing if the 
patient had had fever for <6 days and a clear discharge diagno-
sis of either DF or DHF (based on World Health Organization 
guidelines [34]), which was available for patients who were hos-
pitalized but not for all patients who were not. DENV confir-
mation was previously described in detail by Tissera et al [3]. 
Serum was isolated and stored at −80°C.
Serum Chymase Quantification
Serum chymase levels were measured using the Human Mast 
Cell Chymase I (CMA-I) ELISA Kit (BlueGene Biotech) accord-
ing to the manufacturer’s instructions.
Data Analysis
SPSS (IBM) was used to generate demographic statistics and 
perform relative operating characteristic (ROC) curve analysis. 
For multivariate and univariate analyses, logistic regression was 
performed, with diagnosis (DF or DHF) as a dependent vari-
able, using STATA, version 14. Prism software was used to com-
pare mean chymase levels among groups by 1- or 2-way analysis 
of variance. Results were considered statistically significant if P 
values were <.05. G*Power software was used for post hoc anal-
yses, to verify an observed power of >0.8.
RESULTS
Elevated Serum Chymase Level, a Predictor of DHF
We measured the levels of chymase in the sera of 347 DENV-
infected patients (mean age [±SD], 22.7 ± 14.8 years; Figure 1A) 
who had had fever for ≤6 days at the time of enrollment. Of 
this cohort, 99 (28.6%) received a diagnosis of DHF as a final 
discharge diagnosis. Among patients with DF, 15 of 223 (6.7%) 
also experienced mild hemorrhagic manifestations that did not 
meet the diagnosis criteria for DHF, which was termed “DF 
with bleeding” (DFWB). The dominant serotype of infection 
was DENV-1 (in 85% of infections), followed by DENV-4 (in 
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15%), and most patients (74%) had secondary infections [3]. 
On average, patients were enrolled a mean duration (±SD) of 
4.43 ± 1.2 days after fever onset (Figure 1B), and there was no 
difference in the average day of enrollment between patients 
who received a diagnosis of DF and those who received a diag-
nosis of DHF (Figure 1C). Of the patients for whom the chy-
mase level was measured, 91% were confirmed to be positive for 
DENV by either immunoglobulin M, NS1, and/or polymerase 
chain reaction testing. The blood sample in which the serum 
chymase level was measured was collected at the time of study 
enrollment, when 45.2% of patients were admitted with a diag-
nosis of DF, 7.2% were admitted with a diagnosis of undifferen-
tiated fever or viral fever, 1.1% were admitted with a diagnosis 
of DHF, and 0.8% were admitted with a diagnosis of urinary 
tract infection; for 45.4%, the diagnosis was either undeter-
mined or unreported. Only 4% of patients who ultimately had a 
diagnosis of DHF received this diagnosis at the time of admis-
sion, which is consistent with the prevalent observation that the 
clinical course of DENV disease is difficult to predict during 
acute disease.
Independent variables associated with a diagnosis of DHF 
were investigated by multivariate logistic regression analysis 
(Table 1). Although chymase concentrations were measured in 
the first blood sample, collected at the time of enrollment, data 
on the remaining variables were recorded if they were recorded 
at any time between enrollment and study completion. Of the 
variables considered, serum chymase concentration at the time 
of presentation was a highly predictive biomarker for a DHF 
diagnosis for all patients with a diagnosis of DENV infection 
and for those with confirmed DENV infection (Table 1). Even 
after adjustment for the other variables, the odds of having 
DHF was 1.32 times more likely than the odds of having DF 
(adjusted odds ratio, 1.32; 95% confidence interval, 1.21–1.44) 
with every unit increase in serum chymase level (Table 1). As 
expected, many warning signs associated with subsequent 
development of severe dengue, such as hepatic and abdominal 
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Figure 1. Demographic characteristics and fever duration at the time of recruitment among patients with dengue. A, Age distribution of male and female patients enrolled 
in this study, with a dominance of working-age males. B, Histogram depicting fever duration at the time of patient enrollment. C, There was no significant difference between 
the day of recruitment for patients who received a diagnosis of dengue fever (DF) versus those who received a diagnosis of dengue hemorrhagic fever (DHF) or dengue shock 
syndrome (DSS).
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pain or tenderness, were also significantly associated with DHF. 
Also, as expected, a narrow pulse pressure was significantly 
associated with a DHF diagnosis for patients who received 
a DENV diagnosis (Table 1) but not for the subset with con-
firmed DENV infection (P  =  .06; Table  1 and Supplementary 
Table 2). For patients with confirmed DENV infection, diarrhea 
was significantly associated with receipt of a DHF diagnosis 
(Table 1). Hemorrhagic manifestations, aside from bleeding per 
vaginam, were present in both DF and DHF groups and did not 
discriminate between them (Table 1 and Supplementary Tables 
1 and 2). All recorded variables that were not significantly 
linked with DHF are included in Supplementary Tables 1 and 
2. We found that an early increase in the serum chymase level 
was a significant predictor for subsequent diagnosis of DHF in 
DENV-infected patients before the signs were clinically appar-
ent. The significant link between chymase level and a DHF diag-
nosis was highly correlated for patients with confirmed DENV 
infection (P ≤ .0001; Supplementary Table 2). Serum chymase 
levels were unknown to the clinicians at the time of diagnosis. 
Since approximately 4% of patients with DHF received a DHF 
diagnosis upon admission, we repeated the analysis without 
those patients to ensure that chymase levels were truly prog-
nostic. Indeed, the association between chymase level and DHF 
remained highly significant (P  =  .028). Thus, the serum chy-
mase level is a prognostic biomarker of DHF.
We next compared the mean serum chymase concentra-
tions of patients grouped on the basis of their final diagnosis: 
all patients with a diagnosis of DF; a subset of patients with 
a diagnosis of DF who had signs of bleeding (ie, the DFWB 
group), which was used to understand whether chymase lev-
els also correlated with mild/moderate bleeding; and patients 
with a diagnosis of DHF. Patients with a diagnosis of DHF 
had significantly higher serum chymase levels than all patients 
with a diagnosis of DF and patients with DFWB. Interestingly, 
patients in the DFWB group, who had overt symptoms of 
bleeding yet did not meet the DHF diagnosis criteria, formed 
a discrete group that differed significantly from the DF and 
DHF groups (Figure 2A). Similar results were obtained when 
the analysis was limited to the majority of patients with labo-
ratory-confirmed dengue (Supplementary Figure 1). Grouping 
by age revealed that children and adolescents with DHF had 
higher chymase levels than adults with DHF (Figure 2B). The 
chymase level was also significantly elevated in the serum of 
patients with DHF, compared with the level in patients with 
DF, irrespective of the day of enrollment after fever onset 
(Figure 2C). Thrombocytopenia is a sign of both DF and DHF, 
although a rapid decline in the platelet count can be a warning 
sign of severe dengue [8]. A platelet count of <100 000 is one 
criterion for a DHF diagnosis [8, 35]. However, platelet counts 
for patients in the DF and DHF groups at the time of study 
enrollment did not differ (Figure  2D), even though, at later 
time points, differences in platelet counts became apparent 
(Supplementary Figure 2). These data show that chymase levels 
highly correlate with DENV disease severity.
To test how rigorously the chymase concentration performs 
as a biomarker of severe DENV, we used a ROC analysis. Curves 
were generated by plotting sensitivity against specificity for chy-
mase level as a predictor of DENV severity. In this test, accuracy 
Table 1. Serum Chymase Level and Symptoms Associated With Diagnosis of Dengue Fever (DF) Versus Dengue Hemorrhagic Fever (DHF) Among 334 
Patients With a Diagnosis of Dengue Virus (DENV) Infection and the Subset of 297 Patients With Confirmed DENV Infection
Dengue Sign or Symptom OR (95% CI) aOR (95% CI)
DENV infection diagnosisa
 Chymase level 1.31b (1.20–1.42) 1.32b (1.21–1.44)
 Bleeding per vaginam 3.19 (1.15–8.83) 1.79 (.48–6.61)
 Abdominal pain 2.31 (1.27–4.20) 1.35 (.54–3.41)
 Abdominal tenderness 2.29 (1.21–4.33) 2.57 (.69–9.64)
 Hepatic tenderness 2.08 (1.06–4.08) 0.72 (.21–2.52)
 Narrow pulse pressure 4.04 (.95–17.2) 2.78 (.50–15.4)
 Oliguria 2.72 (1.20–6.20) 2.03 (.67–6.18)
DENV infection confirmationc
 Chymase level 1.30 (1.19–1.43) 1.31 (1.19–1.45)
 Bleeding per vaginam 3.19 (1.23–8.30) 1.55 (.42–5.95)
 Abdominal pain 2.58 (1.37–4.86) 1.58 (.58–4.26)
 Abdominal tenderness 2.40 (1.24–4.65) 1.94 (.47–7.96)
 Hepatic tenderness 2.08 (1.05–4.16) 0.68 (.19–2.47)
 Narrow pulse pressure 2.27 (1.17–4.40) 2.07 (.88–4.86)
 Oliguria 2.71 (1.16–6.29) 2.42 (.83–7.08)
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.
aData are for 223 with DF and 99 with DHF.
bPer unit increase.
cData are for 174 DF and 73 with DHF.
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is measured by the area under the ROC curve, where, by con-
vention, an area of 0.9–1 is considered “excellent,” an area of 
0.8–0.9 is considered “good,” an area of 0.7–0.8 is considered 
“fair,” and an area of <0.7 in considered “poor.” The chymase level 
was, overall, a good predictor of DENV severity (Figure  3A). 
When evaluated in different age groups, chymase concentration 
was an excellent predictor of severity in children and adoles-
cent DENV-infected patients (Supplementary Figure  3A–C). 
Although the chymase level was an excellent predictor of 
severity in adult patients in Singapore who were recruited ≤72 
hours after fever onset (Supplementary Figure 4) [25], in this 
Sri Lankan cohort, where patients were recruited over a lon-
ger time (average, 4.4 days after fever), the chymase level was 
a good predictor of severity (Supplementary Figure  3D). The 
chymase level was a weaker predictor of severity for patients 
aged >45 years, which included elderly adults (Supplementary 
Figure  3E). However, since most patients enrolled very late 
after fever onset, we performed the same analysis for patients 
enrolled <4 days after fever onset. This showed that the chymase 
concentration is an excellent predictor of severity as an early 
biomarker (Figure  3B). The ROC analysis results were highly 
similar for the majority of patients with confirmed DENV 
infection (Figure 3C), compared with all patients with a diag-
nosis of DENV infection (Figure 3A). Analysis of all patients 
recruited days 3–6 after fever onset revealed a sensitivity of 0.96 
and a specificity of 0.79 when a chymase level of 1.5  ng/mL 
was used as a cutoff for DHF (Figure 3D). This cutoff was cho-
sen on the basis of the ROC analysis, to emphasize sensitivity 
over specificity by choosing the maximal sensitivity value that 
retained good specificity. This resulted in a positive predictive 
value of 76%, indicating that 76% of those with chymase levels 
of >1.5ng/mL should develop DHF, and a negative predictive 
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Figure 2. Chymase level is a prognostic biomarker of dengue hemorrhagic fever (DHF). A, Patients with DHF (n = 99) had significantly higher levels of serum chymase as 
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130 and 48, respectively, aged 18–45 years; and 27 and 7, respectively, aged >45 years. C, Chymase levels were significantly elevated in patients with DHF, compared with 
levels among patients with DF, enrolled on days 3–6 after fever onset. Data are for 43 patients with DF and 15 with DHF on day 3; 78 and 36, respectively, on day 4; 63 and 
23, respectively, on day 5; and 30 and 14, respectively, on day 6. D, Platelet counts in acute blood samples collected on the day of study enrollment did not differ between 
DF and DHF groups (analysis was performed using the Student unpaired t test). Error bars represent standard errors of the mean. *P < .05, by 1-way analysis of variance with 
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value of 97%, indicating that 97% of those with chymase lev-
els of <1.5ng/mL should not develop DHF. For patients aged 
0–5 years, a sensitivity of 1 is maintained at this cutoff value. 
For patients aged >45 year, the sensitivity and specificity were 
1.0 and 0.92, respectively (Figure 3). These results confirm that 
an elevated chymase level can identify DHF and DSS with very 
high sensitivity and good specificity for multiple age groups.
PECs Influence Serum Chymase Levels
We assessed whether any PECs could influence chymase lev-
els in DENV-infected patients. PECs were self-reported and 
included obesity, diabetes, and cardiac, musculoskeletal, cere-
brovascular, liver, or lung-associated diseases. The patients’ his-
tory of anemia or gastrointestinal disease had been recorded, but 
none in this cohort had these conditions. The impact of PECs 
on chymase levels was assessed by multivariate analysis with age 
in years as a covariate. This revealed that chymase levels during 
acute dengue are significantly influenced by certain PECs, such 
as diabetes and cardiovascular diseases (Table 2).
We next questioned whether PECs could interfere with the 
capacity of the chymase level predict DHF and DSS. The aver-
age chymase levels in the DF and DHF groups between adult 
patients (age, >18 years) with and those without PECs (no-PEC) 
were compared (Figure 4). The analysis was limited to adults 
since nearly all patients with PECs were adults. For all groups of 
patients with PECs, chymase levels were significantly higher in 
patients who received a DHF diagnosis as compared to patients 
who received a DF diagnosis (Figure 4), emphasizing that none of 
the PECs would prevent the use of chymase level as a biomarker 
of DHF. For patients with any PEC (Figure 4A) and the subset 
of patients with lung-associated diseases or obesity (Figure 4B 
and 4C), patients with DHF had significantly higher levels of 
chymase than no-PEC DHF patients. For patients with car-
diac diseases, diabetes, or musculoskeletal diseases as PECs 
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(Supplementary Figure 5A–C), although the mean levels of chy-
mase were higher, the difference between patients with and those 
without PECs was not statistically significant. Similarly, there was 
a nonsignificant trend toward increased chymase levels in patients 
with DF for certain PECs, such as lung-associated diseases (Figure 
4B). Together, these results emphasize that the chymase concentra-
tion remains a good indicator of DHF in DENV-infected patients 
with PECs and that it is higher in patients with certain types of 
PECs, particularly obesity and lung-associated conditions.
DISCUSSION
Our results highlight the potential of the chymase level to 
be used to predict DHF at the time of initial presentation. 
Importantly, at the time of blood specimen collection, only 4% 
of patients who would ultimately receive a diagnosis of DHF 
had received a DHF diagnosis; yet chymase concentrations 
would have correctly predicted that 96% of those patients would 
develop DHF. Indeed, for all groups of patients recruited in this 
cohort, independent of age, chymase levels were correlated with 
the severity of disease and significantly predicted disease out-
comes according to multiple statistical methods. Interestingly, 
patients with DFWB had significantly higher levels of chymase 
than patients with DF without bleeding, indicating that the chy-
mase level may assist in discriminating within the broad clinical 
spectrum of DF. Other early clinical signs, such as mild bleed-
ing, rash, and low platelet count, were not able to prognosticate 
the subsequent development of DHF. Signs of bleeding or hem-
orrhaging were also not strong predictors of DHF in this cohort, 
most likely because they frequently were present in patients in 
the DFWB group, who did not meet all of the criteria for DHF. 
This emphasizes the long-standing observation that patients 
with DF often experience mild-to-moderate hemorrhagic man-
ifestations that have limited predictive capacity for diagnosing 
DHF. Some warning signs were associated with DHF diagnosis, 
but these occurred late in the development of disease, during 
the transition from acute febrile to defervescent stages, and they 
occurred after an increase in the serum chymase level. One lim-
itation of our study is that more clinical data were available for 
patients who were admitted to the hospital for a longer time and 
that inpatient monitoring was not used for the purposes of col-
lecting data for the study. Therefore, some patients could have 
developed signs or symptoms that were not recorded because 
they had been discharged. The association in our study between 
certain warning signs and DHF could reflect their importance 
to the accepted case definition of severe DENV. Reliance only 
on these clinical signs for DHF diagnosis is not ideal owing to 
their late presentation. Since chymase levels were elevated in 
blood specimens obtained prior to the presentation of most 
warning signs, they can potentially also identify patients who 
may go on to develop severe disease and for whom closer clini-
cal monitoring is warranted.
Table  2. Multivariate Analysis of Preexisting Conditions (PECs) That 
Significantly Influence Serum Chymase Levels During Dengue Virus 
Infection
PEC P
Any .289
Cardiovascular disease <.001
Diabetes <.001
Lung <.001
Obesity <.001
Cerebrovascular disease <.001
Musculoskeletal disease .999
Liver disease <.001
Data were analyzed with chymase concentration as a dependent variable and PECs as 
independent variables.
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Figure 4. Preexisting conditions (PECs) lead to higher chymase levels in patients with dengue hemorrhagic fever (DHF). Comparison of serum chymase levels in healthy 
patients (for no-PEC, DF: n = 191, for no-PEC, DHF: n = 82) versus patients with PECs grouped by all PECs (for PEC, DF: n = 33, for PEC, DHF: n = 17; A), patients with lung-as-
sociated diseases (with-PEC: n = 6-DF, n = 2-DHF; B), and obesity (with-PEC: n = 5-DF, n = 5-DHF; C). For all groups, with-PEC groups were compared to the without-PEC adult 
patients (age, >18 years). Data were analyzed by 2-way analysis of variance with the Sidak multiple comparisons test. Post-hoc power analyses are included in Supplementary 
Table 3. *P < .001.
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Our data indicate that the chymase level is a stronger bio-
marker for children and adolescents than for adults. A  lower 
chymase level in adults with DHF could reflect their increased 
likelihood of having other comorbidities that could exacerbate 
disease or influence the diagnosis of severity, potentially inde-
pendent of vascular complications. Elderly patients frequently 
have atypical dengue presentations and often experience coin-
fections [36]. Older adults may also present later with a febrile 
response after inoculation with virus, which could alter the 
detection parameters and the study time points since they are 
anchored here to the onset of fever. Studies have not identified 
any influence of age on the DENV intrinsic incubation period; 
however, these studies were performed in young adults [37]. 
Even though the oldest adults in this study had lower levels of 
chymase during DHF, a conservative cutoff of 1.5 ng/mL was 
still able to predict DHF in this population with a sensitivity 
approaching 1 and a specificity of >0.95. Further studies are 
needed to determine whether these cutoffs are valid for addi-
tional patient cohorts, including those in other dengue-en-
demic regions.
Previously, we reported that, in a cohort of adult Singaporean 
patients, chymase levels were significantly correlated with dis-
ease severity. Those data had a sensitivity of 1.0, a false-positive 
rate of 0.83, and an area under the ROC curve of 0.99 for adults 
recruited up to 72 hours after fever onset (Supplementary Figure 
4) [25]. In that study, measurement of the chymase concentra-
tion in sequential serum samples showed that levels decreased 
over time as acute disease resolved [25]. In this cohort, patients 
were recruited at longer times after fever onset, but we did not 
observe significant differences between the levels of chymase, 
based on the day of study enrollment. Longitudinal serum 
monitoring of individual patients, which was not performed 
here, might also demonstrate that chymase levels are higher at 
earlier time points. Going forward, it will be important to assess 
whether early measurement of the chymase level and interven-
tion can improve the outcomes of DENV-infected patients and 
promote allocation of healthcare resources to those most likely 
to develop severe DENV.
Our results show that PECs influence the levels of chymase 
during DHF. In particular, the link between high chymase levels 
and DHF in patients with lung-associated PECs is interesting 
because, although the specific conditions were not specified, 
some of these patients presumably had asthma, which has a 
known MC-promoted etiology. In the 1981 Cuban epidemic, 
asthma was also frequently a PEC of patients with DHF [38]. 
Higher chymase levels indicate increased activation of MCs 
in patients with DHF with PECs. Although we previously 
observed that febrile control patients without dengue (most of 
whom had respiratory virus infections) did not have elevated 
chymase levels [25], some other infections activate MCs. One 
patient with DHF in this study had a chymase concentration 
that was approximately 100 times the levels of other patients 
with DHF and received a diagnosis of bacterial coinfection. This 
raises the point that chymase induction is not necessarily DENV 
specific and can be detected in other conditions that promote 
MC activation, including bacterial infections and noninfectious 
inflammatory conditions, such as asthma or anaphylaxis. Thus, 
measurement of the serum chymase level alone should not serve 
as a diagnostic test for DENV and, for DENV infection progno-
sis, must be interpreted in the context of results of other tests 
performed to confirm infection or in the context of a strong sus-
picion of DENV. Furthermore, since PECs influence chymase 
concentrations in DENV-infected patients, additional studies 
should determine whether differing cutoffs for patients with 
PECs would improve the prognostic value of the chymase level.
Our data demonstrate that the chymase concentration is a 
strong predictor of DHF in febrile patients with acute-phase 
DENV infection, with the potential to identify those at risk for 
complications more robustly and at earlier time points than 
many clinical warning signs. Since chymase is an angioten-
sin-converting enzyme and can influence vasoconstriction [28], 
further studies are needed to determine its contributions to the 
pathophysiology of DENV disease.
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